S100A8/A9: a mediator of severe asthma pathogenesis and morbidity?This article is one of a selection of papers published in a special issue celebrating the 125th anniversary of the Faculty of Medicine at the University of Manitoba.
- 1 October 2009
- journal article
- review article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 87 (10), 743-755
- https://doi.org/10.1139/y09-054
Abstract
Nearly 12% of children and 6% of adults in Canada have been diagnosed with asthma. Although in most patients symptoms are controlled by inhaled steroids, a subpopulation (∼10%) characterized by excessive airway neutrophilia, is refractory to treatment; these patients exhibit severe disease, and account for more than 50% of asthma health care costs. These numbers underscore the need to better understand the biology of severe asthma and identify pro-asthma mediators released by cells, such as neutrophils, that are unresponsive to common steroid therapy. This review focuses on a unique protein complex consisting of S100A8 and S100A9. These subunits belong to the large Ca2+-binding S100 protein family and are some of the most abundant proteins in neutrophils and macrophages. S100A8/A9 is a damage-associated molecular pattern (DAMP) protein complex released in abundance in rheumatoid arthritis, inflammatory bowel disease, and cancer, but there are no definitive studies on its role in inflammation and obstructive airways disease. Two receptors for S100A8/A9, the multiligand receptor for advanced glycation end products (RAGE) and Toll-like receptor 4 (TLR4), are expressed in lung. TLR4 is linked with innate immunity that programs local airway inflammation, and RAGE participates in mediating fibroproliferative remodeling in idiopathic pulmonary fibrosis. S100A8/A9 can induce cell proliferation, or apoptosis, inflammation, collagen synthesis, and cell migration. We hypothesize that this capacity suggests S100A8/A9 could underpin chronic airway inflammation and airway remodeling in asthma by inducing effector responses of resident and infiltrating airway cells. This review highlights some key issues related to this hypothesis and provides a template for future research.Keywords
This publication has 98 references indexed in Scilit:
- Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinThe Journal of Experimental Medicine, 2008
- RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesisCarcinogenesis: Integrative Cancer Research, 2008
- Structural and functional insights into RAGE activation by multimeric S100BThe EMBO Journal, 2007
- A need for circulating biomarkers of severe persistent asthma and its treatmentClinical and Experimental Allergy, 2006
- Calcium-dependent and -independent interactions of the S100 protein familyBiochemical Journal, 2006
- S100A8 and S100A9 activate MAP kinase and NF-κB signaling pathways and trigger translocation of RAGE in human prostate cancer cellsExperimental Cell Research, 2006
- Proinflammatory S100 proteins in arthritis and autoimmune diseaseArthritis & Rheumatism, 2004
- S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature)Biochemical and Biophysical Research Communications, 2004
- Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantationAnnals Of The Rheumatic Diseases, 2003
- A soluble protein characteristic of the nervous systemBiochemical and Biophysical Research Communications, 1965